The products of Surtseyan eruptions are generally oxidized palagonite basalts (though andesitic eruptions do occur, albeit rarely), and like Strombolian eruptions Surtseyan eruptions are generally continuous or otherwise rhythmic.A defining feature of a Surtseyan eruption is the formation of a pyroclastic surge (or base surge), a ground hugging radial cloud that develops along with the eruption column. Base surges are caused by the gravitational collapse of a vaporous eruptive column, one that is denser overall than a regular volcanic column. The densest part of the cloud is nearest to the vent, resulting in a wedge shape. Associated with these laterally moving rings are dune-shaped depositions of rock left behind by the lateral movement. These are occasionally disrupted by bomb sags, rock that was flung out by the explosive eruption and followed a ballistic path to the ground. Accumulations of wet, spherical ash known as accretionary lapilli are another common surge indicator.Over time Surtseyan eruptions tend to form maars, broad low-relief volcanic craters dug into the ground, and tuff rings, circular structures built of rapidly quenched lava. These structures are associated with single vent eruptions. However, if eruptions arise along fracture zones, rift zones may be dug out. Such eruptions tend to be more violent than those which form tuff rings or maars, an example being the 1886 eruption of Mount Tarawera. Littoral cones are another hydrovolcanic feature, generated by the explosive deposition of basaltic tephra (although they are not truly volcanic vents).
Decitabine/cedazuridine, sold under the brand name Inqovi, is a fixed-dose combination medication for the treatment of adults with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). It is a combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor.The most common side effects of decitabine/cedazuridine include fatigue, constipation, hemorrhage, muscle pain (myalgia), mucositis (mouth sores), arthralgia (joint pain), nausea, dyspnea, diarrhea, rash, dizziness, fever with low white blood cell count (febrile neutropenia), edema, headache, cough, decreased appetite, upper respiratory tract infection, pneumonia, and transaminase increased. The combination can cause fetal harm.Decitabine/cedazuridine was approved for medical use in the United States and in Canada in July 2020. Medical uses
Decitabine/cedazuridine is indicated for treatment of adults with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.MDS is a type of blood cancer in which blood cells in the bone marrow are defective leading to a low number of one or more types of blood cells. History
Decitabine/cedazuridine was approved for medical use in the United States and in Canada in July 2020.The U.S. Food and Drug Administration (FDA) granted the application of decitabine combined with cedazuridine priority review and orphan drug designation.